GlassScriptPhysician profile
Sara Twist
NPI 1093989774
$3,786.97
in general payments reported to CMS, 2019-2025
19 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $312 · 2023: $917 · 2024: $1,242 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,456.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $776.94 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $714.47 | 2022-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $363.07 | 2022-2025 | |
| Lilly USA, LLC | $358.51 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $334.84 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $331.78 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $297.03 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $107.76 | 2023-2024 | Quviviq |
| Pfizer INC. | $87.60 | 2022-2025 | |
| Viatris Specialty LLC | $59.71 | 2025 | Yupelri |
| Currax Pharmaceuticals LLC | $58.24 | 2022-2023 | Contrave, Onzetra Xsail, Nexlizet |
| Merck Sharp & Dohme LLC | $56.56 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $52.69 | 2022-2023 | Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.33 | 2024-2025 | Jardiance |
| Medicure Pharma INC. | $39.20 | 2024-2025 | Zypitamag |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $37.21 | 2022-2024 | Qsymia |
| Glaxosmithkline, LLC. | $24.31 | 2024 | Shingrix |
| Abbott Laboratories | $22.71 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.01 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Twist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.